Table 1.
In vitro cytotoxicity of gold(III) and zinc(II) porphyrin complexes and cisplatin on human cancerous and normal cell lines
| IC50 values, μM; 72 h | ||||||||
| Complex | A2780 (ovarian cancer) | A2780cis (ovarian cancer, cisplatin-resistant) | NCI-H460 (lung cancer) | MDA-MB-231 (breast cancer) | HepG2 (liver cancer) | HCT116 (colon cancer) | NCM460 (colon epithelial) | CCD-19Lu (lung fibroblast) |
| AuMesoIX | 0.06 ± 0.01 | 0.1 ± 0.01 | 0.07 ± 0.02 | 0.4 ± 0.02 | 0.8 ± 0.06 | 0.06 ± 0.01 | 1.5 ± 0.15 | 0.7 ± 0.04 |
| AuTPP | 0.2 ± 0.02 | 0.1 ± 0.01 | 0.2 ± 0.03 | 0.5 ± 0.03 | 0.3 ± 0.02 | 0.20 ± 0.02 | 0.4 ± 0.03 | 0.4 ± 0.04 |
| AuOEP | 0.3 ± 0.03 | 0.3 ± 0.03 | 0.2 ± 0.04 | 0.7 ± 0.05 | 0.5 ± 0.04 | 0.3 ± 0.02 | 1.4 ± 0.12 | 0.5 ± 0.03 |
| ZnMesoIX | 32.3 ± 6.9 | >100 | 15.5 ± 1.4 | 84.3 ± 9.6 | >100 | 10.2 ± 1.2 | >100 | >100 |
| ZnTPP | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| ZnOEP | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| Cisplatin | 0.7 ± 0.1 | 26.2 ± 1.9 | 3.7 ± 0.7 | 35.5 ± 1.5 | 22.3 ± 3.2 | 10.1 ± 2.2 | 93.8 ± 8.9 | 30.8 ± 4.9 |